Barclays’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Barclays’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,144	Closed	-$1.73M	–	5391
2020 Q4	$1.73M	Sell	13,144 -762	-5%	-$67.3K	﹤0.01%	2352
2020 Q3	$704K	Buy	13,906 +2,234	+19%	+$100K	﹤0.01%	2965
2020 Q2	$557K	Buy	11,672 +4,149	+55%	+$193K	﹤0.01%	3257
2020 Q1	$369K	Sell	7,523 -18,834	-71%	-$959K	﹤0.01%	3831
2019 Q4	$1.51M	Sell	26,357 -5,671	-18%	-$281K	﹤0.01%	3274
2019 Q3	$1.15M	Buy	32,028 +4,510	+16%	+$176K	﹤0.01%	3524
2019 Q2	$855K	Sell	27,518 -6,574	-19%	-$178K	﹤0.01%	3849
2019 Q1	$799K	Buy	34,092 +18,392	+117%	+$295K	﹤0.01%	3655
2018 Q4	$216K	Sell	15,700 -1,816	-10%	-$22.9K	﹤0.01%	4522
2018 Q3	$175K	Buy	+17,516	New	+$288K	﹤0.01%	5114

Barclays's EIDX Position: Q1 2021 in Review

Barclays sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 13,144 shares — an estimated $1.73M sold.

Barclays first reported a position in EIDX in Q3 2018 and held it in 10 quarters. The position peaked at $1.73M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Barclays reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Barclays sold 13,144 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $1.73M.
Barclays first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
Barclays's Eidos Therapeutics, Inc. Common Stock position peaked at $1.73M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.